LONP1 and AL amyloidosis: The highly potent and proteasome-specific drug carfilzomib in combination with the LonP1-inhibitor CDDO-Me should synergistically enhance protein stress within multiple myeloma cells, while bortezomib, a baseline inhibitor of LonP1 and less potent proteasome inhibitor, may not derive a synergistic benefit with addition of CDDO-Me.